Marian E Major

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi request reprint Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees
    Marian E Major
    Laboratory of Hepatitis Viruses, Division of Viral Products Center for Biologics Evaluation and Research Food and Drug Administration, Bethesda, MD, USA
    Hepatology 39:1709-20. 2004
  2. pmc Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees
    Michelina Nascimbeni
    Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 77:4781-93. 2003
  3. ncbi request reprint CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus
    Montserrat Puig
    Laboratory of Hepatitis Viruses, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Hepatology 44:736-45. 2006
  4. pmc Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge
    Marian E Major
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, National Institute of Diabetes and Digestive and Kidney Diseases NIH, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Virol 76:6586-95. 2002
  5. pmc Long-term persistence of infection in chimpanzees inoculated with an infectious hepatitis C virus clone is associated with a decrease in the viral amino acid substitution rate and low levels of heterogeneity
    Javier Fernandez
    Laboratory of Hepatitis Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Building 29A, Room 1D10, HVM 448, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Virol 78:9782-9. 2004
  6. ncbi request reprint Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection
    Montserrat Puig
    Laboratory of Hepatitis Viruses, Division of Viral Products, CBER, FDA, Building 29A, Room 1D02, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Vaccine 22:991-1000. 2004
  7. ncbi request reprint Sensitivity and reproducibility of HCV quantitation in chimpanzee sera using TaqMan real-time PCR assay
    Montserrat Puig
    Laboratory of Hepatitis Viruses, Division of Viral Products, CBER, FDA, Building 29A, Room 1D02, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Virol Methods 105:253-63. 2002
  8. doi request reprint Prospects for prophylactic and therapeutic vaccines against hepatitis C virus
    Stephen M Feinstone
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Clin Infect Dis 55:S25-32. 2012
  9. doi request reprint New neutralizing antibody epitopes in hepatitis C virus envelope glycoproteins are revealed by dissecting peptide recognition profiles
    Alla Kachko
    Laboratory of Hepatitis Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Vaccine 30:69-77. 2011
  10. pmc Inhibition of hepatitis C virus by the cyanobacterial protein Microcystis viridis lectin: mechanistic differences between the high-mannose specific lectins MVL, CV-N, and GNA
    Alla Kachko
    Laboratory of Hepatitis Viruses, Division of Viral Products, Microscopy and Imaging Core Facility, and Laboratory of Method Development, Division of Viral Products, Center for Biologics Evaluation and Research, U S Food and Drug Administration, Bethesda, Maryland 20892, United States
    Mol Pharm 10:4590-602. 2013

Collaborators

  • B Rehermann
  • Richard M Siegel
  • Jeffrey I Cohen
  • Harel Dahari
  • Grigori G Prikhod'ko
  • A U Neumann
  • R E Lanford
  • Geert Leroux-Roels
  • Stephen M Feinstone
  • Montserrat Puig
  • Alla Kachko
  • Kathleen Mihalik
  • Frances Wells
  • Iryna Zubkova
  • Charles M Rice
  • Ollie Williams
  • Michael Merchlinsky
  • Brett D Lindenbach
  • Javier Fernandez
  • Elena A Prikhod'ko
  • Michelina Nascimbeni
  • Hong Lou
  • Carole A Bewley
  • Steven Rubin
  • Sandra Loesgen
  • Kazuyo Takeda
  • Wendy Tan
  • Syed Shahzad-ul-hussan
  • Dale J Hu
  • Sergei Netesov
  • Valeriy Loktev
  • Aleksander Shvalov
  • Hisayoshi Watanabe
  • Antonina Grazhdantseva
  • Galina Sivolobova
  • Alla Ivanova
  • Galina Kochneva
  • Tatyana Lupan
  • Jane A McKeating
  • Alexander Ploss
  • Philip Meuleman
  • Thomas Vanwolleghem
  • Andrew J Syder
  • John C Tilton
  • Mark Connors
  • Peter Thompson
  • Deborah Taylor
  • Duncan R Morhardt
  • Youkyung Hwang Choi
  • Markus Bosmann
  • Curt H Hagedorn
  • Eishiro Mizukoshi
  • John E LaVoy
  • Mei ying Yu

Detail Information

Publications13

  1. ncbi request reprint Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees
    Marian E Major
    Laboratory of Hepatitis Viruses, Division of Viral Products Center for Biologics Evaluation and Research Food and Drug Administration, Bethesda, MD, USA
    Hepatology 39:1709-20. 2004
    ..However, the pathogenesis of HCV may be determined by a more rapid onset of the induced response and the cell population that migrates to the liver...
  2. pmc Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees
    Michelina Nascimbeni
    Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 77:4781-93. 2003
    ..The rate of HCV clearance following reexposure depends on the cellular immune response, the quality and quantity of which may vary among chimpanzees that recovered from HCV infection...
  3. ncbi request reprint CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus
    Montserrat Puig
    Laboratory of Hepatitis Viruses, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Hepatology 44:736-45. 2006
    ..Vaccines that can induce strong T-cell responses prior to challenge will not necessarily prevent persistent HCV infection...
  4. pmc Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge
    Marian E Major
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, National Institute of Diabetes and Digestive and Kidney Diseases NIH, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Virol 76:6586-95. 2002
    ..These observations have encouraging implications for the development of a vaccine for HCV...
  5. pmc Long-term persistence of infection in chimpanzees inoculated with an infectious hepatitis C virus clone is associated with a decrease in the viral amino acid substitution rate and low levels of heterogeneity
    Javier Fernandez
    Laboratory of Hepatitis Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Building 29A, Room 1D10, HVM 448, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Virol 78:9782-9. 2004
    ..These data also indicate that immune pressure and selection continue throughout the chronic phase...
  6. ncbi request reprint Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection
    Montserrat Puig
    Laboratory of Hepatitis Viruses, Division of Viral Products, CBER, FDA, Building 29A, Room 1D02, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Vaccine 22:991-1000. 2004
    ..This data indicates that a strategy inducing a T-cell immune response combined with antibody responses to E1E2 would make a viable candidate for an HCV vaccine...
  7. ncbi request reprint Sensitivity and reproducibility of HCV quantitation in chimpanzee sera using TaqMan real-time PCR assay
    Montserrat Puig
    Laboratory of Hepatitis Viruses, Division of Viral Products, CBER, FDA, Building 29A, Room 1D02, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Virol Methods 105:253-63. 2002
    ....
  8. doi request reprint Prospects for prophylactic and therapeutic vaccines against hepatitis C virus
    Stephen M Feinstone
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Clin Infect Dis 55:S25-32. 2012
    ..This review summarizes the current state of HCV vaccines and the challenges faced for future development and clinical trial design...
  9. doi request reprint New neutralizing antibody epitopes in hepatitis C virus envelope glycoproteins are revealed by dissecting peptide recognition profiles
    Alla Kachko
    Laboratory of Hepatitis Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Vaccine 30:69-77. 2011
    ....
  10. pmc Inhibition of hepatitis C virus by the cyanobacterial protein Microcystis viridis lectin: mechanistic differences between the high-mannose specific lectins MVL, CV-N, and GNA
    Alla Kachko
    Laboratory of Hepatitis Viruses, Division of Viral Products, Microscopy and Imaging Core Facility, and Laboratory of Method Development, Division of Viral Products, Center for Biologics Evaluation and Research, U S Food and Drug Administration, Bethesda, Maryland 20892, United States
    Mol Pharm 10:4590-602. 2013
    ..Overall, the data suggest MVL and CV-N have the potential for toxicity due to interactions with cellular proteins while GNA may be a better therapeutic agent due to specificity for the HCV gpE1E2. ..
  11. ncbi request reprint The NS3 protein of hepatitis C virus induces caspase-8-mediated apoptosis independent of its protease or helicase activities
    Elena A Prikhod'ko
    Medical Virology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Virology 329:53-67. 2004
    ..These findings suggest that HCV NS3 promotes caspase-8 induced apoptosis at a pathway site distal to FADD, and that flavivirus NS3 may represent a new class of pro-apoptotic proteins...
  12. pmc Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro
    Brett D Lindenbach
    Center for the Study of Hepatitis C, Laboratory of Virology and Infectious Disease, The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 103:3805-9. 2006
    ..These results greatly extend the utility of the HCVcc genetic system to allow the complete in vitro and in vivo dissection of the HCV life cycle...
  13. ncbi request reprint Analysis of mutant NS5B proteins encoded by isolates from chimpanzees chronically infected following clonal HCV RNA inoculation
    Hong Lou
    Department of Medicine and Genetics Program Winship Cancer Center, Emory University School of Medicine, Atlanta, GA 30322, USA
    Virology 317:65-72. 2003
    ..The results demonstrate that some in vivo mutations of NS5B directly enhance in vitro RdRp activity. In addition, they suggest that the in vitro RdRp activity of NS5B may not always reflect in vivo activity within replication complexes...